TIMI Study Group

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online. timi.org/40th-anniversa…

Vasoactive treatment in cardiogenic shock varies widely across CICUs, driven by patient-level factors and institutional practice patterns @TIMIStudyGroup @DrRobRoswell @ICUDocAP @TIMIStudyGroup ahajournals.org/doi/10.1161/CI…

TIMI Senior Investigator @DrM_ODonoghue interviewed for @TIME article on important blood tests everyone should be getting. time.com/article/2026/0…

Lp(a) in @CNBC with TIMI Senior Investigator @DrM_ODonoghue cnbc.com/2026/04/27/lpa…

Listen again to the TIMI Talks podcast episode with legendary cardiologist and TIMI Study Group founder Dr. Eugene Braunwald, where he discussed his illustrious career and the beginnings of TIMI. @ddbergMD timi.org/2023/04/14/tim…

Eugene Braunwald, ‘Icon’ of Modern Cardiology, Dies at 96 tctmd.com/news/eugene-br…

While he touched many lives, we at TIMI were truly blessed to directly work with and learn from him over treasured decades. We will deeply miss him, but take comfort in knowing that we will carry forward his legacy and continue his lifelong mission to advance cardiovascular care.

More than 40 years, 80 clinical trials, and 450,000 trial participants later, we are proud that the TIMI Study Group has impacted almost every facet of cardiovascular care. Dr. Braunwald’s intellectual rigor and zeal for discovery were legendary.

We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.

Simulation from large US cohort of ACS pts shows triple lipid Rx (↑-intensity statin, ezetimibe, PCSK9i) before discharge would achieve LDL <55 mg/dL in 99.8% & <40 mg/dL in 98.7% of pts, w/a 36% further ↓ in CV events @ 5 yrs c/w ↑-intensity statin monotherapy @rgiugliano

TIMI Senior Investigator @DrM_ODonoghue reports for @Medscape on the new 2026 ACC/AHA #dyslipidemia guidelines medscape.com/viewarticle/ne…

TIMI Investigator @marstonMD's #ACC26 LBCT #VESALIUS presentation covered in @MGBResearchNews @ebohula @rgiugliano massgeneralbrigham.org/en/about/newsr…

TIMI Investigator @BrianBergmark presents two LBCT’s at #EuroPCR 2026 - 19/5 (#VESALIUS results of #evolocumab in pts w/coronary stenting) & 20/5 (Long-term mortality following PCI with DES vs. CABG for left main disease) @ebohula @rgiugliano @PCRonline pcronline.com/Courses/EuroPC…

#ACC26 LBCT presentation of ESSENCE TIMI 73b substudy covered in @NewsMedical @marstonMD news-medical.net/news/20260330/…

In a pre-specified secondary analysis of the Essence-TIMI 73b RCT, #olezarsen’s TG lowering effects appeared greater in patients on background fibrates, supporting further study of combination therapy with APOC3 inhibition. @AnnabelZWang @BrianBergmark

Serum lactate offers imperfect risk stratification for death in most CS pts w/SL btw 0-5 mmol/L regardless of CS phenotype. Pts presenting with minimally elevated or normal serum lactate still experience very ↑ in-hospital mortality >25% @CCCTNetwork @EmilyMarogi #ACC26

Results out now in @CircAHA ahajournals.org/doi/10.1161/CI…

Primary results of ESSENCE-CCTA trial: Among pts w/ mod hypertriglyceridemia, tx w/#olezarsen substantially ↓ triglycerides & remnant cholesterol, modestly ↓ apoB, but did not affect NCPV @ 12 mos. A CV outcomes trial would determine whether long-term APOC3i ↓ CV events #ACC26

In a large CICU validation cohort of predictive biomarkers, FGF-23, GDF-15, & sST2 discriminated cardiogenic shock from non-shock controls, while FGF-23 also distinguished cardiogenic from distributive shock & was independently assoc w/in-hospital mortality @NicholasChiuMD #ACC26

Coverage in @medical_xpress of @marstonMD's LBCT presentation at #ACC26 showing #evolocumab very effective in high risk patients with no known ASCVD @ebohula @rgiugliano msn.com/en-us/health/d…